162 related articles for article (PubMed ID: 31564931)
1. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons.
Tremblay G; Westley T; Cappelleri JC; Arondekar B; Chan G; Bell TJ; Briggs A
Clinicoecon Outcomes Res; 2019; 11():551-565. PubMed ID: 31564931
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
3. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H; Wen X; Zheng H
Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
[TBL] [Abstract][Full Text] [Related]
8. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
10. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
[No Abstract] [Full Text] [Related]
11. Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
Tremblay G; Daniele P; Bell T; Chan G; Brown A; Cappelleri JC
J Comp Eff Res; 2021 May; 10(7):603-612. PubMed ID: 33733815
[No Abstract] [Full Text] [Related]
12. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Swaminathan M; Kantarjian HM; Levis M; Guerra V; Borthakur G; Alvarado Y; DiNardo CD; Kadia T; Garcia-Manero G; Ohanian M; Daver N; Konopleva M; Pemmaraju N; Ferrajoli A; Andreeff M; Jain N; Estrov Z; Jabbour EJ; Wierda WG; Pierce S; Pinsoy MR; Xiao L; Ravandi F; Cortes JE
Haematologica; 2021 Aug; 106(8):2121-2130. PubMed ID: 33853292
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
16. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
[TBL] [Abstract][Full Text] [Related]
17. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Laloi L; Billotey NC; Dumas PY; Paul F; Villate A; Simand C; Fornecker L; Puisset F; Bertoli S; Simonet MB; Laribi K; Houyou D; Santagostino A; Michel C; Guepin GR; Guerineau E; Tabrizi R; Hunault M; Giltat A; Kaphan E; Bulabois C; Cartet E; Rocher C; Lachenal F; Morisset S; Récher C; Pigneux A; Belhabri A; Michallet M; Michallet AS
Cancer Med; 2023 Mar; 12(6):7175-7181. PubMed ID: 36482507
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Berdel AF; Koch R; Gerss J; Hentrich M; Peceny R; Bartscht T; Steffen B; Bischoff M; Spiekermann K; Angenendt L; Mikesch JH; Kewitz T; Butterfass-Bahloul T; Serve H; Lenz G; Berdel WE; Krug U; Schliemann C
Ann Hematol; 2023 Jan; 102(1):63-72. PubMed ID: 36399194
[TBL] [Abstract][Full Text] [Related]
19. Glasdegib in the treatment of acute myeloid leukemia.
Wolska-Washer A; Robak T
Future Oncol; 2019 Oct; 15(28):3219-3232. PubMed ID: 31432695
[TBL] [Abstract][Full Text] [Related]
20. Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis.
Colunga-Lozano LE; Kenji Nampo F; Agarwal A; Desai P; Litzow M; Sekeres MA; Guyatt GH; Brignardello-Petersen R
PLoS One; 2022; 17(2):e0263240. PubMed ID: 35108310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
